Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257044 · ClinicalTrials.gov registry record · Phase 1
Acute Effects of Cannabigerol
A Phase 1 study, sponsored by Washington State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05257044 is a Phase 1 study that has completed, run by Washington State University. The registered enrollment target is 38 participants.
The verdict
NCT05257044, a Phase 1 study, has completed, sponsored by Washington State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of hemp-derived cannabigerol (CBG) on anxiety, stress, mood, and cognition. Further, the severity of various side effects of CBG (sleepiness, dry mouth, dry eyes, increased appetite) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.
Interventions
- OTHER Placebo
- DRUG Cannabigerol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257044
The ClinicalTrials.gov registry entry for NCT05257044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05257044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05257044 about?
NCT05257044 is a clinical study titled "Acute Effects of Cannabigerol". The purpose of this study is to examine the effects of hemp-derived cannabigerol (CBG) on anxiety, stress, mood, and cognition. Further, the severity of various side effects of CBG (sleepiness, dry mouth, dry eyes, increased appetite) will be assessed. As such, the study is focused on better underst...
What is the current status of trial NCT05257044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-03-24. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT05257044?
The interventions under investigation include: Placebo (OTHER), Cannabigerol (DRUG).
Who is sponsoring clinical trial NCT05257044?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.